Back to Journals » OncoTargets and Therapy » Volume 11

The putative tumor suppressor, miR-199a, regulated by Snail, modulates clear cell renal cell carcinoma aggressiveness by repressing ROCK1

Authors Zhang X, Li P, Ding Z, Wang H, Wang J, Han L, Ding S

Received 25 July 2017

Accepted for publication 11 November 2017

Published 27 December 2017 Volume 2018:11 Pages 103—112

DOI https://doi.org/10.2147/OTT.S147184

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Tohru Yamada


Xiao Zhang,1 Peng Li,1 Zhen Ding,1 Huili Wang,1 Junye Wang,1 Lei Han,1 Shangwei Ding2

1Department of Oncology, Affiliated Hospital of Jining Medical University, Jining, Shandong, 2Department of Ultrasound, Dongguan People’s Hospital Affiliated to Southern Medical University, Dongguan, Guangdong, China

Background: Aberrant expression of miR-199a has been frequently reported in cancer studies; however, its role in renal cell carcinoma (RCC) has not been examined in detail.
Results: Here, we showed that miR-199a was downregulated in RCC and associated with poor prognostic phenotype. Using luciferase and western blot assays we identified that Rho-associated coiled coil-containing protein kinases 1 (ROCK1) was a direct target gene for miR-199a. miR-199a regulated proliferation, invasion, and apoptosis of clear cell renal cell carcinoma (ccRCC) cells by modulating ROCK1 expression. Interestingly, we also found that miR-199a was modulated by snail in ccRCC cells. Snail elevated ROCK1 expression by repressing miR-199a activity.
Conclusion: Altogether, our results identify a crucial tumor suppressive role of miR-199a in the progression of ccRCC and suggest that miR-199a might be an anticancer therapeutic target for ccRCC patients.

Keywords: clear cell renal cell carcinoma, miR-199a, ROCK1, Snail, A498

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]